Medicus Pharma (NASDAQ:MDCX) Announces Earnings Results

Medicus Pharma (NASDAQ:MDCX) announced its quarterly earnings results on Friday. The company reported ($11.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.68) by ($4.96), FiscalAI reports.

Medicus Pharma Trading Up 2.2%

Shares of NASDAQ:MDCX traded up $0.04 on Friday, hitting $1.87. The company had a trading volume of 29,253 shares, compared to its average volume of 97,217. Medicus Pharma has a 1-year low of $1.70 and a 1-year high of $127.50. The stock has a market cap of $2.36 million, a price-to-earnings ratio of -0.02 and a beta of 0.80. The stock has a 50 day moving average price of $6.14 and a 200 day moving average price of $21.72.

Analysts Set New Price Targets

Several research firms have issued reports on MDCX. Weiss Ratings upgraded Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 30th. Wall Street Zen upgraded Medicus Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 31st. Finally, Alliance Global Partners reiterated a “buy” rating on shares of Medicus Pharma in a research note on Monday, September 14th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $450.00.

About Medicus Pharma

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes.

Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.